- Home
- AVNS vs REPL Comparison
AVNS vs REPL Comparison
Compare AVNS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVNS
- REPL
- Stock Information
- Founded
- AVNS 2014
- REPL 2015
- Country
- AVNS United States
- REPL United States
- Employees
- AVNS N/A
- REPL N/A
- Industry
- AVNS Industrial Specialties
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- AVNS Health Care
- REPL Health Care
- Exchange
- AVNS Nasdaq
- REPL Nasdaq
- Market Cap
- AVNS 938.0M
- REPL 816.4M
- IPO Year
- AVNS N/A
- REPL 2018
- Fundamental
- Price
- AVNS $18.59
- REPL $14.93
- Analyst Decision
- AVNS Hold
- REPL Strong Buy
- Analyst Count
- AVNS 1
- REPL 5
- Target Price
- AVNS N/A
- REPL $17.20
- AVG Volume (30 Days)
- AVNS 319.0K
- REPL 803.0K
- Earning Date
- AVNS 10-30-2024
- REPL 11-12-2024
- Dividend Yield
- AVNS N/A
- REPL N/A
- EPS Growth
- AVNS N/A
- REPL N/A
- EPS
- AVNS 0.34
- REPL N/A
- Revenue
- AVNS $681,500,000.00
- REPL N/A
- Revenue This Year
- AVNS $3.84
- REPL N/A
- Revenue Next Year
- AVNS $4.04
- REPL $469.74
- P/E Ratio
- AVNS $39.49
- REPL N/A
- Revenue Growth
- AVNS N/A
- REPL N/A
- 52 Week Low
- AVNS $17.39
- REPL $4.92
- 52 Week High
- AVNS $25.36
- REPL $16.55
- Technical
- Relative Strength Index (RSI)
- AVNS 37.25
- REPL 72.52
- Support Level
- AVNS $17.49
- REPL $10.57
- Resistance Level
- AVNS $21.12
- REPL $12.73
- Average True Range (ATR)
- AVNS 0.62
- REPL 0.84
- MACD
- AVNS -0.07
- REPL 0.10
- Stochastic Oscillator
- AVNS 30.30
- REPL 72.91
About AVNS Avanos Medical Inc.
Avanos Medical Inc is a United States-based company that develops and sells medical devices and related services globally. Its operating and reportable segment provides medical device products to healthcare providers and patients. The company has now changed two franchises: has combined Chronic Care and Pain Management franchises into a single commercial organization focused on the Digestive Health and Pain Management and Recovery product categories that generate its revenue from its Chronic Care franchise and in North America.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.